CG ONCOLOGY INC (CGON) Stock Price & Overview
NASDAQ:CGON • US1569441009
Current stock price
The current stock price of CGON is 68.87 USD. Today CGON is up by 3.81%. In the past month the price increased by 2.93%. In the past year, price increased by 221.42%.
CGON Key Statistics
- Market Cap
- 5.815B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.09
- Dividend Yield
- N/A
CGON Stock Performance
CGON Stock Chart
CGON Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CGON. When comparing the yearly performance of all stocks, CGON is one of the better performing stocks in the market, outperforming 96.6% of all stocks.
CGON Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CGON. The financial health of CGON is average, but there are quite some concerns on its profitability.
CGON Earnings
On February 27, 2026 CGON reported an EPS of -0.53 and a revenue of 2.32M. The company beat EPS expectations (15.43% surprise) and beat revenue expectations (379.26% surprise).
CGON Forecast & Estimates
21 analysts have analysed CGON and the average price target is 86.39 USD. This implies a price increase of 25.43% is expected in the next year compared to the current price of 68.87.
For the next year, analysts expect an EPS growth of -22.78% and a revenue growth 1006.85% for CGON
CGON Groups
Sector & Classification
CGON Financial Highlights
Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS decreased by -47.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.34% | ||
| ROE | -21.39% | ||
| Debt/Equity | 0 |
CGON Ownership
CGON Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.26 | 369.653B | ||
| AMGN | AMGEN INC | 15.49 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.61 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 16 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.64 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 11 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.15 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.53 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CGON
Company Profile
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 142 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Company Info
IPO: 2024-01-25
CG ONCOLOGY INC
400 Spectrum Center Drive, Suite 2040
Irvine CALIFORNIA US
Employees: 142
Phone: 13025310855
CG ONCOLOGY INC / CGON FAQ
Can you describe the business of CG ONCOLOGY INC?
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 142 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Can you provide the latest stock price for CG ONCOLOGY INC?
The current stock price of CGON is 68.87 USD. The price increased by 3.81% in the last trading session.
Does CG ONCOLOGY INC pay dividends?
CGON does not pay a dividend.
What is the ChartMill technical and fundamental rating of CGON stock?
CGON has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists CGON stock?
CGON stock is listed on the Nasdaq exchange.
What is the analyst forecast for CGON stock?
21 analysts have analysed CGON and the average price target is 86.39 USD. This implies a price increase of 25.43% is expected in the next year compared to the current price of 68.87.
Can you provide the PE ratio for CGON stock?
CG ONCOLOGY INC (CGON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.09).